|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Philadelphia_chromosome-positive_leukemia
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:approves
|
gptkb:2007
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Tasigna
|
|
gptkbp:class
|
quinazoline derivative
|
|
gptkbp:clinical_trial
|
second-line treatment
first-line treatment
NC T00450164
resistant CML
|
|
gptkbp:contraindication
|
QT prolongation
hypersensitivity to nilotinib
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:dosage_form
|
gptkb:tablet
300 mg twice daily
400 mg once daily
|
|
gptkbp:excretion
|
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nilotinib
|
|
gptkbp:ingredients
|
C28 H31 N7 O2 S
|
|
gptkbp:interacts_with
|
gptkb:HIV_protease_inhibitors
gptkb:warfarin
antacids
certain antibiotics
certain antifungals
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
gptkb:2023
patented
|
|
gptkbp:is_monitored_by
|
electrocardiogram
liver function tests
blood counts
|
|
gptkbp:is_used_for
|
gptkb:chronic_myeloid_leukemia
|
|
gptkbp:lifespan
|
approximately 15 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:operational_status
|
approved
|
|
gptkbp:pharmacokinetics
|
included
|
|
gptkbp:research_areas
|
oncology
hematology
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
rash
cardiovascular events
pulmonary hypertension
hypoglycemia
hepatotoxicity
pancreatitis
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:BCR-ABL_fusion_protein
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:weight
|
481.66 g/mol
|